BOSTON and ROCHESTER, N.Y., Aug. 6, 2014 (GLOBE NEWSWIRE) -- Caliber Imaging & Diagnostics (OTCQB:LCDX), formerly Lucid, Inc., was featured in a news segment on NBC4 affiliate in Los Angeles (KNBC-TV) and an accompanying online article on July 10.
The health report by Dr. Bruce Hensel, titled "High-Tech System Detects Skin Cancer Without Biopsy," focuses on the Company's VivaScan™ procedure using a VivaScope®, which can aide in the detection of skin cancer and eliminate unnecessary biopsies. The segment interviews a patient who undergoes a VivaScan administered by Dr. Babar Rao at NIDIskin (Non-Invasive Diagnostic Imaging of the Skin) Consulting, located at 8383 Wilshire Boulevard in Beverly Hills, California.
To view the segment in its entirety and read the article, please visit the following link:
The video at the link above is provided for informational purposes only. Caliber Imaging & Diagnostics is not responsible for the content of the linked video.
About Caliber Imaging & Diagnostics
Caliber Imaging & Diagnostics' proprietary, cutting-edge VivaScope® system is a disruptive, noninvasive point-of-care platform imaging technology with numerous applications in dermatology, surgery and research. FDA 510(k) cleared, VivaScope has regulatory approval in most major markets. With 78 issued and pending patents worldwide, VivaScope has the potential to significantly improve outcomes and reduce costs. The VivaScan™ procedure, which utilizes the VivaScope for dermatological examination, allows physicians to detect cancerous lesions that appear benign, and reduces the need for expensive, painful and time-consuming biopsies, which show no malignancy approximately 70% of the time. VivaScope also has significant applications in testing and analysis in the academic, medical and therapeutic research markets. For more information about Caliber I.D. and its products, please visit www.caliberid.com.
VivaScope® is a registered trademark of Caliber Imaging & Diagnostics.
VivaScan™ is a trademark of Caliber Imaging and Diagnostics.
This press release contains "forward looking statements" within the meaning of the Securities Litigation Reform Act of 1995, including the statements regarding the potential for future product revenue growth and financial performance. These statements are based on our current beliefs or expectations and are inherently subject to significant known and unknown uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved and actual results may differ materially from our beliefs or expectations due to financial, economic, business, regulatory and other factors or conditions affecting us or our industry in general, as well as more specific risks and uncertainties facing us, such as those set forth in the Risk Factors section of the Forms 10-Q and 10-K filed by us with the Securities and Exchange Commission.
CONTACT: Caliber Imaging & Diagnostics Richard Christopher Chief Financial Officer (617) 348-9821 firstname.lastname@example.org or Dian Griesel Int'l. Susan Forman or Laura Radocaj (212) 825-3210 email@example.com firstname.lastname@example.orgSource:Caliber Imaging & Diagnostics, Inc.